---
title: "Early Morning Trend | LUYE PHARMA retraces to the stage low, can sector linkage change the weakness?"
description: "LUYE PHARMA (2186.HK) has recently seen its stock price continue to decline, temporarily retracing to the previous low point area. The daily death cross signal is clear, and the short-term bearish atm"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274119354.md"
published_at: "2026-01-30T01:00:00.000Z"
---

# Early Morning Trend | LUYE PHARMA retraces to the stage low, can sector linkage change the weakness?

> LUYE PHARMA (2186.HK) has recently seen its stock price continue to decline, temporarily retracing to the previous low point area. The daily death cross signal is clear, and the short-term bearish atmosphere dominates the market. From a technical perspective, major indicators such as MACD and RSI are showing weakness, with the 5-day and 10-day moving averages continuing to decline, and the K-line combination leaning towards bearish, indicating ongoing market selling pressure. 

On the fundamental side, although LUYE PHARMA has launched some new drugs, the industry as a whole has entered a complex phase of stricter policy regulation, price reductions in medical insurance, and high R&D investments, which affects performance improvement in the short term due to various uncertainties. The overall performance of the pharmaceutical sector has seen a recent decline in participation enthusiasm, with major institutions preferring defensive industries or rotating into high-growth areas. 

In terms of sector linkage, the pharmaceutical sector is weak, with noticeable short-term capital outflows. LUYE PHARMA is constrained by the overall atmosphere, facing systemic adjustment pressure brought about by the industry's "collective bearish" sentiment. In the current sensitive range of the retracement phase, both institutions and short-term funds remain highly sensitive, with price fluctuations easily triggering sector resonance. 

For future trends, attention should be paid to whether the support at this low point is effective. If strong support is breached, short-term bearish signals may further strengthen; conversely, if funds provide support and lead to a reversal of indicators, there may be a technical rebound in the short term. Investors should strictly control risks, primarily adopting a wait-and-see approach when the bottom is unclear, and if making tentative layouts, set appropriate stop-loss levels

LUYE PHARMA (2186.HK) has recently seen its stock price continue to decline, temporarily retracing to the previous low point area. The daily death cross signal is clear, and the short-term bearish atmosphere dominates the market. From a technical perspective, major indicators such as MACD and RSI are showing weakness, with the 5-day and 10-day moving averages continuing to decline, and the K-line combination leaning towards bearish, indicating ongoing market selling pressure.

On the fundamental side, although LUYE PHARMA has launched some new drugs, the industry as a whole has entered a complex phase of stricter policy regulation, price reductions in medical insurance, and high R&D investments, with many uncertainties affecting short-term performance improvement. The overall performance of the pharmaceutical sector has seen a recent decline in participation enthusiasm, with major institutions preferring defensive industries or rotating into high-growth areas.

In terms of sector linkage, the pharmaceutical sector is weak, with noticeable short-term outflows of funds. LUYE PHARMA is constrained by the overall atmosphere, facing systemic adjustment pressure brought about by the industry's "collective bearish" sentiment. In the current sensitive range of the retracement phase, both institutions and short-term funds remain highly sensitive, with price fluctuations easily triggering sector resonance.

For the subsequent trend, attention needs to be paid to whether the support at this low point is effective. If strong support is breached, short-term bearish signals may further strengthen; conversely, if funds provide support and lead to a reversal of indicators, there may be a short-term technical rebound. Investors should strictly control risks, and when the bottom is unclear, it is advisable to remain on the sidelines. If making tentative layouts, stop-loss levels should be set.

In summary, LUYE PHARMA is currently still in a weak position. During the downward phase, it is essential to closely monitor fund movements and overall market sentiment, as the sector linkage mechanism is unlikely to improve the weakness significantly. Caution is advised for low buying and quick entry and exit operations

### Related Stocks

- [02186.HK - LUYE PHARMA](https://longbridge.com/en/quote/02186.HK.md)
- [01530.HK - 3SBIO](https://longbridge.com/en/quote/01530.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 早盘趋势｜中国生物制药回踩低点，反弹窗口会否开启？ | 中国生物制药（1177.HK）近期股价持续低位震荡整理，日线呈现小幅阴阳交替，整体重心下移。近几个交易日，股价回踩至前低区间附近，成交量持续萎缩，场内增量资金观望情绪浓厚。从技术面看，MACD 指标依旧死叉，绿柱显著，短线多空分歧较大。 基 | [Link](https://longbridge.com/en/news/274497353.md) |
| 早盘趋势｜三生制药缩量下行，支撑保卫战要开始？ | 1 月 21 日收盘，三生制药（1530.HK）继续震荡下探，盘中成交量持续萎缩，主力资金观望情绪浓厚，抢反弹力量有限。日线级 MACD 死叉形态延续，绿柱扩展，弱势格局短时间内难以逆转。整体来看，市场主导情绪仍为防御，短线资金多数选择快进 | [Link](https://longbridge.com/en/news/273204377.md) |
| 早盘趋势｜重塑能源缩量盘跌，板块分化中短线机会浮现？ | 2 月 3 日，重塑能源（2570.HK）日 K 线再度下跌，主力拐点尚未明显。新能源赛道整体持续疲弱，内部分化加剧，尤其氢能源本周无落地利好，板块资金流出十分明显。MACD 日线死叉随盘面同步出现，5 日、10 日、20 日均线集体下穿， | [Link](https://longbridge.com/en/news/274627877.md) |
| 恒基地产 (12.HK)：降准政策护航，低位吸筹意愿上升，短线观望情绪未消 | 2 月 3 日，恒基地产整体温和放量，盘中一度触及技术上轨后小幅震荡。地产板块在降准与宽松预期下低位吸筹趋势明显，主力资金持续流入。港地产新项目获批及新房成交环比改善，为市场提供正面信号，上周资金轮动提振板块短线热度。 全天分时资金多轮交替 | [Link](https://longbridge.com/en/news/274629761.md) |
| 最好的进攻策略是拥有坚实的防守 | 投资者涌向防御性股票  一场安静但强大的轮动正在进行中。消费品类股票相对于非必需品类股票的表现是几十年来最强劲的，苹果的表现像是一个对冲工具，投资者为安全支付了增长倍数。但在今天的市场中，防御性股票已不再便宜。以下是一些图表，稍微揭示了当前 | [Link](https://longbridge.com/en/news/276433851.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
